Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
7.10
+0.05 (0.71%)
At close: Nov 18, 2026, 4:00 PM EST
7.10
0.00 (-0.07%)
After-hours: Nov 18, 2026, 7:30 PM EST
Precision BioSciences Revenue
Precision BioSciences had revenue of $45.04M in the twelve months ending September 30, 2026, up 6,353.01% year-over-year. In the year 2025, Precision BioSciences had annual revenue of $34.26M, down -50.12%. That makes Precision BioSciences the 28,742nd largest company in the world by revenue and 3,849th in the United States.
Revenue (ttm)
$45.04M
Revenue Growth
+6,353.01%
P/S Ratio
6.02
Revenue / Employee
$652,783
Employees
69
Market Cap
271.01M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 34.26M | -34.43M | -50.12% |
| Dec 31, 2024 | 68.70M | 19.97M | 40.98% |
| Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
| Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
| Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
| Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
| Dec 31, 2019 | 22.24M | 11.36M | 104.34% |
| Dec 31, 2018 | 10.88M | 4.40M | 67.84% |
| Dec 31, 2017 | 6.48M | -531.00K | -7.57% |
| Dec 31, 2016 | 7.02M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 133.95M |
| Fulcrum Therapeutics | 80.00M |
| Editas Medicine | 49.83M |
| X4 Pharmaceuticals | 16.96M |
| Scribe Therapeutics | 14.83M |
| Allogene Therapeutics | 4.64M |
| SAB Biotherapeutics | 114.70K |
DTIL News
- 8 days ago - Precision BioSciences management to meet virtually with Oppenheimer - TheFly
- 8 days ago - Precision BioSciences Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - Precision BioSciences Transcript: KOL event - Transcripts
- 9 days ago - Precision BioSciences Slides: KOL event - Filings
- 13 days ago - Precision BioSciences announces PBGENE-HBV data at AASLD The Liver Meeting - TheFly
- 13 days ago - Precision BioSciences announces PBGENE-HBV data at AASLD The Liver Meeting - TheFly
- 13 days ago - Precision BioSciences prices 10.24M shares at $7.75 in underwritten offering - TheFly
- 13 days ago - Precision BioSciences says DSMB review supports additional PBGENE-DMD dosing - TheFly